BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10510915)

  • 21. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.
    Wang W; Yuasa T; Tsuchiya N; Maita S; Kumazawa T; Inoue T; Saito M; Ma Z; Obara T; Tsuruta H; Satoh S; Habuchi T
    Endocr Relat Cancer; 2008 Dec; 15(4):943-52. PubMed ID: 18667685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy.
    Ziaran S; Goncalves FM; Wendl J; Trebaticky B; Breza JS
    Bratisl Lek Listy; 2009; 110(9):559-62. PubMed ID: 19827339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
    Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J; Morote J; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX
    BJU Int; 2007 Apr; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF
    J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
    Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.
    Ziaran S; Goncalves FM; Breza JS
    Endocr Regul; 2011 Oct; 45(4):199-204. PubMed ID: 22073949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
    J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
    Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
    J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
    Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy.
    Kim SH; Seong do H; Yoon SM; Choi YD; Song Y; Song H; Choi E
    Eur J Oncol Nurs; 2016 Apr; 21():197-204. PubMed ID: 26522218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of androgen deprivation therapy on hip geometric properties and bone mineral density in Japanese men with prostate cancer and its relationship with the visceral fat accumulation.
    Watanabe D; Kimura T; Yamashita A; Minowa T; Miura K; Mizushima A
    Aging Male; 2020 Dec; 23(5):1158-1164. PubMed ID: 31959023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J; Morin JP; Orsola A; Abascal JM; Salvador C; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.